App-Quantinova.ai

EVALUATION OF DIFFERENT ESTIMATED GLOMERULAR FILTRATION RATE AS RELIABLE MEASURES OF RENAL FUNCTION IN CHILDREN WITH SICKLE CELL DISEASE

Ilaria Liguoro - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

RISK OF SERIOUS INFECTIONS IN PATIENTS WITH OR WITHOUT PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A REAL-WORLD MATCHED COHORT ANALYSIS

Bhumika J Patel - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Paroxysmal nocturnal hemoglobinuria

N/A

IBERDOMIDE (IBER) IN COMBINATION WITH DEXAMETHASONE (DEX) AND DARATUMUMAB (DARA), BORTEZOMIB (BORT), OR CARFILZOMIB (CFZ) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Sagar Lonial - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

DYSREGULATION OF CHROMATIN MODIFIERS DRIVES LINEAGE SWITCH IN MLL-R ACUTE LEUKEMIA

Ricky Tirtakusuma - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute Leukemia

Blinatumomab

DREAMM-5 PLATFORM TRIAL: BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH FIVE DIFFERENT NOVEL AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Paul G Richardson - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

GSK2857916

RESULTS FROM A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

Kevin H.M. Kuo - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Beta-thalassemia

Adenosine-5'-triphosphate

VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4-YEAR FOLLOW-UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY

Othman Al-Sawaf - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Obinutuzumab

PHASE I/II UPDATED SAFETY AND EFFICACY RESULTS OF ORAL BRUTON TYROSINE KINASE (BTK) INHIBITOR RILZABRUTINIB IN RELAPSED/REFRACTORY IMMUNE THROMBOCYTOPENIA (ITP)

David J. Kuter - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

L-Tyrosine

THE BURDEN OF SICKLE CELL DISEASE (SCD) ON PATIENTS IN GHANA AND NIGERIA COMPARED WITH OTHER LOW-/MIDDLE-INCOME AND HIGH-INCOME COUNTRIES: RESULTS FROM THE SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)

Ifeyinwa Osunkwo - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

CLONAL HAEMATOPOIESIS PROMOTES ADVERSE OUTCOMES IN CHRONIC KIDNEY DISEASE

Ahmed Dawoud - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

End stage renal disease

CystC

MATCHING ADJUSTED INDIRECT COMPARISON OF CILTACABTAGENE AUTOLEUCEL VERSUS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH ≥3 LINES OF PRIOR THERAPY

Katja Weisel - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

GSK2857916

NAVITOCLAX AND RUXOLITINIB FOR PATIENTS WITH MYELOFIBROSIS AND JAK INHIBITOR EXPERIENCE: RESPONSE DURATION IN PHASE 2 STUDY

Claire Harrison - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITUTION REDUCES TOXICITY WHILE MAINTAINING EFFICACY FOR THE TREATMENT OF ADVANCED-STAGE HODGKIN LYMPHOMA.

Anna Santarsieri - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

dacarbazine Intravenous

REDEFINING OUTCOMES IN MULTIPLE MYELOMA IN COVID-19 INFECTED PATIENTS. RECONSIDERING THE THROMBOSIS AND INFECTIVE RISK.

Harberth Fernandez-Leyva - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Multiple Myeloma

Dexamethasone

MAGROLIMAB + AZACITIDINE VERSUS AZACITIDINE + PLACEBO IN UNTREATED, HIGHER-RISK (HR) MYELODYSPLASTIC SYNDROME: THE PHASE 3, RANDOMIZED, ENHANCE STUDY

Guillermo Garcia-Manero - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Alpha-thalassemia myelodysplasia syndrome

Vidaza

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON JAK2 INHIBITOR THERAPY AND REQUIRING RBC TRANSFUSIONS (INDEPENDENCE TRIAL)

Ruben Mesa - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

Pomalidomide

CHARACTERIZATION OF OCULAR ADVERSE EVENTS IN PATIENTS RECEIVING BELANTAMAB MAFADOTIN FOR ≥12 MONTHS: POST-HOC ANALYSIS OF DREAMM-2 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sagar Lonial - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

GSK2857916

NILOTINIB INHIBITS INFLAMMATION IN ACUTE MYELOID LEUKEMIA

Jose Luis Marin-Rubio - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Nilotinib

IMPACT OF EARLY RESPONSE ON OUTCOMES IN AL AMYLOIDOSIS FOLLOWING TREATMENT WITH FRONTLINE BORTEZOMIB

Sriram Ravichandran - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

AL Amyloidosis

Bortezomib

THE PATIENT EXPERIENCE OF MULTIPLE MYELOMA: SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE

Courtney Levy - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Filters

45280 Abstracts